Article Abstract

What’s new in the treatment of advanced small-cell lung cancer

Authors: Jia-Tao Zhang, Hao-Ran Zhai, Zhong-Yi Dong, Yi-Long Wu, Wen-Zhao Zhong


Small-cell lung cancer (SCLC) represents one of the most aggressive cancer types, and it is associated with a dismal prognosis throughout the world. However, the lack of evidence regarding a suitable therapy regimen makes the systemic treatment of SCLC problematic. In recent years, with the rapid development of high-throughput sequencing and immunotherapy, several existing regimens have been shown to be promising for future treatment. Several treatment regimens, including immunotherapy, Rova-T, and alisertib, have led to considerable response rates and manageable side effects. Immunotherapy and antibodydrug conjugates (ADCs) should be examined closely in subsequent assays and clinical trials. Here, we reviewed some of the latest and most promising treatment strategies for SCLC with the aim of elucidating the full scope of SCLC treatment.